Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models

Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models

Abstract Abnormalities in brains of Alzheimer's disease (AD) patients are thought to start long before the first clinical symptoms emerge. The identification of affected individuals at this ‘preclinical AD’ stage relies on biomarkers such as decreased levels of the amyloid‐β peptide (Aβ) in the...

Full description

Bibliographic Details
Main Authors: Luis F Maia, Stephan A Kaeser, Julia Reichwald, Marius Lambert, Ulrike Obermüller, Juliane Schelle, Jörg Odenthal, Peter Martus, Matthias Staufenbiel, Mathias Jucker
Format: Article
Language:English
Published: Springer Nature 2015-05-01
Series:EMBO Molecular Medicine
Subjects:
Alzheimer's disease
Aβ
biomarker
CSF
preclinical
Online Access:https://doi.org/10.15252/emmm.201505026

Internet

https://doi.org/10.15252/emmm.201505026

Similar Items